Esperion Therapeutics, Inc. (0IIM.L)
USD 2.27
(-8.85%)
USD 2.27
(-8.85%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 540.94 Million USD | 107.3% |
| 2022 | 260.94 Million USD | 0.29% |
| 2021 | 260.19 Million USD | 40.34% |
| 2020 | 185.4 Million USD | 11762.32% |
| 2019 | 1.56 Million USD | 0.0% |
| 2018 | - USD | -100.0% |
| 2017 | 1.04 Million USD | -61.74% |
| 2016 | 2.73 Million USD | -36.37% |
| 2015 | 4.29 Million USD | -13.06% |
| 2014 | 4.93 Million USD | 0.0% |
| 2013 | - USD | -100.0% |
| 2012 | 22.76 Million USD | 230.13% |
| 2011 | 6.89 Million USD | 0.0% |
| 2002 | 8.79 Million USD | 38.57% |
| 2001 | 6.34 Million USD | 70.38% |
| 2000 | 3.72 Million USD | 33.99% |
| 1999 | 2.77 Million USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 556.63 Million USD | 1.41% |
| 2024 Q1 | 548.87 Million USD | 1.46% |
| 2023 Q3 | 264.13 Million USD | 0.38% |
| 2023 FY | 540.94 Million USD | 107.3% |
| 2023 Q4 | 540.94 Million USD | 104.8% |
| 2023 Q2 | 263.12 Million USD | 0.66% |
| 2023 Q1 | 261.4 Million USD | 0.17% |
| 2022 Q3 | 260.22 Million USD | 0.02% |
| 2022 FY | 260.94 Million USD | 0.29% |
| 2022 Q4 | 260.94 Million USD | 0.28% |
| 2022 Q2 | 260.17 Million USD | 0.01% |
| 2022 Q1 | 260.15 Million USD | -0.01% |
| 2021 Q4 | 260.19 Million USD | -5.8% |
| 2021 FY | 260.19 Million USD | 40.34% |
| 2021 Q3 | 276.22 Million USD | -0.05% |
| 2021 Q2 | 276.36 Million USD | -0.07% |
| 2021 Q1 | 276.55 Million USD | 49.16% |
| 2020 Q1 | 5.63 Million USD | 260.33% |
| 2020 Q3 | 6.73 Million USD | 8.66% |
| 2020 FY | 185.4 Million USD | 11762.32% |
| 2020 Q2 | 6.19 Million USD | 10.07% |
| 2020 Q4 | 185.4 Million USD | 2652.49% |
| 2019 Q3 | 1.08 Million USD | 13.47% |
| 2019 Q4 | 1.56 Million USD | 43.79% |
| 2019 FY | 1.56 Million USD | 0.0% |
| 2019 Q1 | 976 Thousand USD | 0.0% |
| 2019 Q2 | 958 Thousand USD | -1.84% |
| 2018 Q3 | - USD | -100.0% |
| 2018 Q1 | 603 Thousand USD | -42.3% |
| 2018 FY | - USD | -100.0% |
| 2018 Q4 | - USD | 0.0% |
| 2018 Q2 | 152 Thousand USD | -74.79% |
| 2017 Q4 | 1.04 Million USD | -29.34% |
| 2017 Q2 | 1.9 Million USD | -18.0% |
| 2017 Q1 | 2.32 Million USD | -14.98% |
| 2017 FY | 1.04 Million USD | -61.74% |
| 2017 Q3 | 1.47 Million USD | -22.32% |
| 2016 Q1 | 3.91 Million USD | -8.85% |
| 2016 FY | 2.73 Million USD | -36.37% |
| 2016 Q4 | 2.73 Million USD | -12.83% |
| 2016 Q2 | 3.52 Million USD | -9.84% |
| 2016 Q3 | 3.13 Million USD | -11.17% |
| 2015 Q4 | 4.29 Million USD | -7.94% |
| 2015 FY | 4.29 Million USD | -13.06% |
| 2015 Q1 | 4.88 Million USD | -1.05% |
| 2015 Q2 | 4.9 Million USD | 0.31% |
| 2015 Q3 | 4.66 Million USD | -4.86% |
| 2014 Q1 | - USD | 0.0% |
| 2014 Q3 | 4.92 Million USD | 0.14% |
| 2014 Q4 | 4.93 Million USD | 0.16% |
| 2014 FY | 4.93 Million USD | 0.0% |
| 2014 Q2 | 4.92 Million USD | 0.0% |
| 2013 Q1 | - USD | -100.0% |
| 2013 Q2 | - USD | 0.0% |
| 2013 Q3 | - USD | 0.0% |
| 2013 Q4 | - USD | 0.0% |
| 2013 FY | - USD | -100.0% |
| 2012 Q4 | 22.76 Million USD | 0.0% |
| 2012 FY | 22.76 Million USD | 230.13% |
| 2011 FY | 6.89 Million USD | 0.0% |
| 2003 Q1 | 8.8 Million USD | 0.11% |
| 2003 Q3 | 9.12 Million USD | 0.84% |
| 2003 Q2 | 9.05 Million USD | 2.82% |
| 2002 FY | 8.79 Million USD | 38.57% |
| 2002 Q2 | 8.39 Million USD | 5.06% |
| 2002 Q3 | 8.19 Million USD | -2.34% |
| 2002 Q1 | 7.98 Million USD | 25.89% |
| 2002 Q4 | 8.79 Million USD | 7.27% |
| 2001 Q2 | 6.2 Million USD | 54.97% |
| 2001 Q4 | 6.34 Million USD | 0.11% |
| 2001 FY | 6.34 Million USD | 70.38% |
| 2001 Q1 | 4 Million USD | 7.52% |
| 2001 Q3 | 6.33 Million USD | 2.14% |
| 2000 Q1 | 2.61 Million USD | 0.0% |
| 2000 FY | 3.72 Million USD | 33.99% |
| 2000 Q2 | 2.47 Million USD | -5.69% |
| 2000 Q3 | 2.97 Million USD | 20.57% |
| 2000 Q4 | 3.72 Million USD | 25.05% |
| 1999 FY | 2.77 Million USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Editas Medicine, Inc. | 36.53 Million USD | -1380.586% |
| Dynavax Technologies Corporation | 256.91 Million USD | -110.556% |
| Supernus Pharmaceuticals, Inc. | 41.52 Million USD | -1202.639% |
| Perrigo Company plc | 4.07 Billion USD | 86.72% |
| Illumina, Inc. | 2.26 Billion USD | 76.085% |
| Thermo Fisher Scientific Inc. | 34.91 Billion USD | 98.451% |
| Iovance Biotherapeutics, Inc. | 1 Million USD | -53994.7% |
| Walgreens Boots Alliance, Inc. | 9.55 Billion USD | 94.338% |
| IQVIA Holdings Inc. | 14.23 Billion USD | 96.199% |
| Heron Therapeutics, Inc. | 173.75 Million USD | -211.331% |
| Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 79.986% |
| Unity Biotechnology, Inc. | 26.99 Million USD | -1904.25% |
| Waters Corporation | 2.35 Billion USD | 77.035% |
| Biogen Inc. | 7.33 Billion USD | 92.628% |
| Sangamo Therapeutics, Inc. | 38.1 Million USD | -1319.659% |
| Evolus, Inc. | 126.54 Million USD | -327.471% |
| Adicet Bio, Inc. | 17.7 Million USD | -2955.68% |
| Cara Therapeutics, Inc. | 43.16 Million USD | -1153.149% |
| bluebird bio, Inc. | 330.32 Million USD | -63.762% |
| FibroGen, Inc. | 170.45 Million USD | -217.355% |
| Agilent Technologies, Inc. | 2.73 Billion USD | 80.221% |
| Corbus Pharmaceuticals Holdings, Inc. | 20.88 Million USD | -2490.217% |
| Homology Medicines, Inc. | 44.05 Million USD | -1127.918% |
| Geron Corporation | 85.89 Million USD | -529.748% |
| Alnylam Pharmaceuticals, Inc. | 2.39 Billion USD | 77.442% |
| Amicus Therapeutics, Inc. | 445.05 Million USD | -21.545% |
| Myriad Genetics, Inc. | 145 Million USD | -273.067% |
| Viking Therapeutics, Inc. | 1.26 Million USD | -42832.302% |
| Intellia Therapeutics, Inc. | 115.34 Million USD | -368.978% |
| Zoetis Inc. | 6.8 Billion USD | 92.048% |
| Abeona Therapeutics Inc. | 4.4 Million USD | -12188.664% |
| Mettler-Toledo International Inc. | 2.16 Billion USD | 75.046% |
| BioMarin Pharmaceutical Inc. | 1.13 Billion USD | 52.292% |
| Vertex Pharmaceuticals Incorporated | 808.4 Million USD | 33.084% |
| Kala Pharmaceuticals, Inc. | 36.32 Million USD | -1389.269% |
| Ionis Pharmaceuticals, Inc. | 1.45 Billion USD | 62.784% |
| Atara Biotherapeutics, Inc. | 57.87 Million USD | -834.73% |
| Verastem, Inc. | 41.55 Million USD | -1201.699% |
| Nektar Therapeutics | 230.4 Million USD | -134.785% |
| Axsome Therapeutics, Inc. | 186.37 Million USD | -190.251% |
| Aclaris Therapeutics, Inc. | 3.07 Million USD | -17497.495% |
| Sarepta Therapeutics, Inc. | 1.39 Billion USD | 61.273% |
| OPKO Health, Inc. | 326.56 Million USD | -65.648% |
| Exelixis, Inc. | 189.94 Million USD | -184.793% |
| Neurocrine Biosciences, Inc. | 428.4 Million USD | -26.271% |
| Corcept Therapeutics Incorporated | 151 Thousand USD | -358143.046% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| uniQure N.V. | 138.4 Million USD | -290.832% |
| Imunon, Inc. | 1.13 Million USD | -47380.938% |
| Blueprint Medicines Corporation | 774.12 Million USD | 30.121% |
| Insmed Incorporated | 1.2 Billion USD | 55.071% |
| Halozyme Therapeutics, Inc. | 1.49 Billion USD | 63.919% |
| Agios Pharmaceuticals, Inc. | 56.98 Million USD | -849.23% |
| TG Therapeutics, Inc. | 110.79 Million USD | -388.241% |
| Incyte Corporation | 38.28 Million USD | -1312.874% |
| Emergent BioSolutions Inc. | 877.5 Million USD | 38.354% |